Our Approach

A Novel Approach to Treating Pain

We are advancing one of the largest, exclusively pain-focused clinical pipelines of novel, non-opioid therapies in order to bridge the safety and efficacy gaps in current chronic pain treatment. Our lead therapy, CNTX-4975, is based on our proprietary STRATITM technology that provides rapid onset, high degree and long duration of relief from localized moderate to severe pain. CNTX-4975 is currently in late-stage development for the treatment of moderate to severe pain from osteoarthritis (OA), Morton’s neuroma and canine OA pain in pet dogs. The Phase 3 human OA program initiated in February 2018.

Our Strategy

At Centrexion, we’re redefining the study of new pain therapies by using a three-pronged approach:

  1. big data analytics to reveal the pain pathways where our analgesics will have the maximum therapeutic effect
  2. translational science to validate the safety and efficacy of our therapies in companion animals with the same naturally-occurring chronic pain conditions as humans and
  3. innovative, more efficient early-stage clinical trial strategies to inform and de-risk development.



By combining big data analytics with our existing translational medicine activities, such as our veterinary clinical studies and our innovative clinical trial approach that capitalizes on advances made in disease areas such as oncology, we have a more fully informed basis for indication selection and clinical development of our pain treatments.

  • Our partnership with InveniAI (formerly known as BioXcel), a pioneer in cloud-based pharma big data analytic solutions, provides a more informed, data-driven approach to how we develop new therapies to treat pain. Computer and expert analysis of extensive multidisciplinary databases of normal and disease processes provide valuable insights into the pain conditions for which our analgesics could be developed.
  • Through our programs in human and canine OA pain, we are uniquely positioned to better understand the safety and efficacy of CNTX-4975. Companion animals naturally suffer from OA, much like humans, and the development of a veterinary program in dogs allows us to obtain insights into the safety and efficacy of CNTX-4975 that will inform and guide the path for human development.
  • We are capitalizing on innovations from fields such as cancer drug development, leveraging early stage clinical trial designs to quickly and efficiently investigate multiple indications and identifying those that are most likely to respond to a particular treatment.

We believe this comprehensive approach uniquely positions us to more efficiently and effectively develop novel therapies to address a broad range of chronic pain indications.

Why Pain?

Chronic pain is a growing problemnot only in terms of the significant number of people that are impacted and the burden this places on our healthcare system, but also because of the abuse and addiction issues, as well as deaths that have arisen from the high use of opioids to treat chronic pain.

Currently available non-opioid treatments, while avoiding the abuse and addiction issues associated with opioid treatments, offer limited pain relief but significant risks such as gastrointestinal, cardiovascular, central nervous system, renal and other adverse effects, including organ failure and death.

Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic.

Learn More